P53 peptide vaccines are experimental preparations used in cancer immunotherapy research aimed at stimulating the immune response associated with the recognition of the p53 protein. This term does not mean a single molecule, a single amino acid sequence, or a standardized drug. Published approaches include synthetic peptide mixtures and dendritic cells prepared using selected peptide antigens. Each of these methods requires a separate description and evaluation of the scientific evidence. [1] [2]
The most important distinction concerns the induction of an immune response and the improvement of clinical outcomes. The vaccine may lead to detectable T-lymphocyte activity in response to p53, without simultaneously demonstrating a reduction in tumor size, prevention of disease recurrence, or prolongation of survival. This distinction should serve as the basis for both terminology and the interpretation of study results.
What are p53 peptide vaccines? Names, synonyms, and identity
The starting point is the distinction between the molecular target and the intervention being studied. TP53 is a gene; p53 is a protein encoded by it; and the antigenic peptide is a selected fragment of the protein sequence or, in some strategies, a related sequence selected to elicit a specific immune response.
The vaccine, on the other hand, is a complete experimental preparation. These are four distinct concepts, even if the publication uses similar terminology.
Precision is of particular importance in oncology, where the same protein can be the subject of research into vaccines, regulation using small molecules, gene interventions, and engineered intracellular peptides.
The term „vaccine” also requires a proper context. In the studies discussed, researchers generally aimed to influence the immune response associated with an existing cancer disease, rather than preventing a contagious disease.
The studies therefore concerned therapeutic immunization or clinical situations following surgical treatment of a tumor, and not routine prophylactic vaccinations in healthy individuals.
This distinction changes the way results are evaluated. The production of antigen-specific T lymphocytes is an early stage of the study, whereas reducing the number of relapses or improving survival are separate clinical questions.
p53 is a protein encoded by the TP53 gene. In the studies discussed here, it serves as a target for recognition by the immune system, while the term „peptide vaccine” describes one of the ways in which antigen material is presented to the immune system.
P53 protein and a vaccine containing selected p53-related sequences are not the same substance.
The following terms appear in the literature, among others:
- p53 synthetic long peptide vaccine – a vaccine containing synthetic long peptides of p53;
- p53-SLP – an abbreviation referring to vaccines based on long synthetic peptides;
- wild-type p53 peptide vaccine – a peptide vaccine that uses the wild-type p53 sequence;
- p53 peptide-pulsed dendritic cell vaccine – a vaccine containing dendritic cells prepared using p53 peptides.
Additional terms are important. For example, in the study of colon cancer, ten overlapping long peptides were used; in the study of ovarian cancer, a selected fragment of p53 was used in a direct peptide formulation or in an approach using dendritic cells.[1][2]
The term „p53-targeted therapy” is even more broad. It can include immunological approaches, interventions that affect p53 regulation, and other research strategies.
The publication should not be considered evidence regarding peptide vaccines solely because its title contains the words „p53” and „peptide”.
Similar caution is required when searching for company names and patents. A patent may describe a proposed molecular structure or invention, but it does not prove that the solution has been effectively tested in humans.
Without the patent number and the defined patent claims, the term „p53 peptide patent” does not allow identifying a specific vaccine.
How are p53 peptide vaccines classified? Peptide, protein, mixture, or other substance?
Peptide antigens can be chemically identified based on their amino acid sequences, but the identity of the vaccine goes beyond the sequences themselves.
Two formulations can use the same epitope but differ in the carrier material, the method of presenting the antigen, the components that modulate the immune response, and the biological system responsible for presenting the antigen.
These differences can affect both the measured immunogenicity and the type and frequency of adverse events.
Therefore, it would be scientifically unjustified to present a single common percentage of responses for all p53 peptide vaccines.
Short epiphases and longer overlapping sequences also represent different design solutions.
The short peptide may strongly depend on the presentation by a specific HLA molecule. A longer sequence may require processing by the cell before the appropriate epitopes are presented.
The length alone does not prove the superiority of any of these solutions.
Similarly, idiotypic peptides derived from antibodies and peptides directly derived from p53 can be discussed within a similar immunological concept, although they differ in sequence and the intended mode of recognition.
Peptide antigens are chains of amino acids, but a complete intervention usually involves more than an isolated peptide.
It may contain several sequences and components that support the immune response. In vaccines based on dendritic cells, the cells exposed to peptides constitute an important part of the product under study.[3]
| Research approach | Composition or action of interventions | Important distinction |
|---|---|---|
| Vaccine with long synthetic peptides | Several longer antigenic sequences in one formulation | A defined mixture of peptides, not a single universal p53 molecule |
| Vaccine with selected short peptides | Specific epitopes selected for antigenic presentation | HLA compatibility may limit the appropriate population |
| Vaccine from dendrite cells loaded with peptides | Cells presenting the antigen prepared with selected peptides | The cell platform, the preparation of which affects the product's properties |
| The approach with idiotypic peptides | Peptides derived from antibodies against p53 | Related to p53 resistance, but not simply fragments of this protein |
| Stabilized peptide mimicking p53 (stapled peptide) | Designed peptide influencing protein interactions | It is not automatically a vaccine |
The idiotic approach shows why the origin of the sequence matters.
In one of the early studies, eight peptides derived from regions that determine the complementarity of human antibodies against p53 were used.
Terminating these components as „eight fragments of p53” would be a misidentification of the intervention.[4]
The structure and composition of p53 peptide vaccines – what has been established?
For each investigational product, a useful description of the identity should include the peptide sequence and its position relative to the reference p53 protein, information about the use of wild-type or modified sequences, the number of peptides in the mixture, the amount of each peptide, and components that support the immune response or provide the antigen.
For cell products, additional information is required, such as the source of the cells, the preparation method, the method of introducing the antigen, and appropriate quality specifications.
These data are necessary to reproduce the results, and not just to give the preparation a convenient name.
The residues amino acid designations, such as 264–272, show the importance of the parent sequence and the adopted numbering system.
Such a sequence describes the region of the larger protein. It does not constitute a standalone amino acid sequence or evidence that a particular patient's cancer presents a given epitope.
The vaccine may contain a properly synthesized fragment, yet it still encounters biological barriers related to the processing, presentation, and recognition of the antigen.
Molecular accuracy is a prerequisite for mechanistic interpretation, but it does not guarantee effectiveness.
There is no single summary pattern or single molecular mass that describes the entire category of p53 peptide vaccines.
Reproducible identification requires the provision of individual sequences, their length, modifications, the proportions of peptides, the components of the formulation, and, if applicable, the characteristics of the cellular preparation.
These details determine whether the two studies analyzed comparable materials.
In one ovarian cancer study, a fragment of the wild-type p53 protein was used, comprising the remaining residues 264–272 in patients selected based on the presence of HLA-A2.1.
The peptide formulation was compared with dendritic cells prepared using the peptide, and the protocol also included an additional immunomodulatory intervention.
The fragment number identifies the region of the parent protein. It is not a general product name that can be applied to all p53 vaccines.[2]
In the study of head and neck tumors, two modified p53 peptides presented by HLA class I were used, and the groups differed in the way the auxiliary peptides were used.
Modifying the sequence and including auxiliary antigens were intentional elements of the project.
A summary limited to the expression „peptide p53” would hide key differences that are crucial for interpreting the experiment.[3]
The formulations of the long peptides also differed between the studies.
In an early publication on ovarian cancer, ten overlapping peptides were described, while in a later combined study nine were used.
Therefore, the evidence should be attributed to the actual protocol, and not solely because both publications use the term p53-SLP. [5] [6]
Studies on p53 peptide vaccines – evidence in humans, animals and in the laboratory
Publications about people should be treated as a collection of separate, early research programs, not as a single combined clinical study.
They differed in their targets, patient populations, antigenic preparations, and accompanying interventions.
The common observation that the immune response can be measured does not eliminate these differences.
It also does not prove that the magnitude of the laboratory response predicts the clinical outcome of a particular patient.
When comparing the results, it is first necessary to determine how many patients were included in the study, how many actually received the intervention, and how many samples were available for evaluation at the individual time points.
Loss of participants during follow-up is particularly important in small oncology studies, where deterioration in clinical status or changes in treatment may limit the number of people available for subsequent immunological assessments.
The percentage calculated among the participants evaluated may be mathematically correct, but it can be misleading if presented as the percentage of all originally enrolled patients.
Studies of the immune response in humans
In the Phase I/II study of colon cancer, ten patients received a vaccine containing long peptides.
Nine patients showed a measurable response of p53-specific T lymphocytes, and in six of the nine evaluated patients the response persisted for at least six months.
These results confirm immunogenicity under the study conditions, but do not demonstrate superiority in terms of survival compared to the corresponding control group.[1]
In the ovarian cancer study, 20 patients were included, 18 of whom were immunized.
The reactions associated with the vaccine were mostly of a local nature and of minor severity.
Immunological responses were detected in patients who completed the scheduled vaccinations, but disease stabilization was the best reported clinical outcome only in two of the 20 included patients.
The researchers did not establish a link between the induced immune response and this clinical outcome.[5]
In the next publication, the later clinical results were compared with the historical control group.
No improvement in response to the next chemotherapy or survival characteristic of the disease was detected.
Historical comparisons have limitations, but this negative clinical outcome provides a significant context for previous immunological observations.
Further observation should not be counted as a completely independent study of efficacy. [7]
Cellular vaccines and combination therapies
In the phase I study on head and neck tumors, dendritic cells prepared using peptides were evaluated in 16 patients.
In 11 cases, an increase in the frequency of p53-specific T lymphocytes was observed, while in four cases interferon gamma secretion was detected.
The reported disease-free survival was assessed as promising, however, a small study did not establish the causal effect of the vaccine on survival compared to the corresponding untreated control group.[3]
A separate Phase I/II study on ovarian cancer combined chemotherapy, an interferon preparation, and the p53-SLP vaccine.
In the vaccinated group, strong immune responses associated with the vaccine were observed.
Because the intervention involved several active components in small groups, neither the tumor outcomes nor the adverse events could be automatically attributed to the peptides themselves.[6]
Evidence from animals and laboratory studies
The study of idiotypic peptides included both patients and animals.
Responses to the administered peptides were demonstrated, but no T-cell responses characteristic of p53 were observed in human participants.
This illustrates an important problem of specificity: the response to the components of the vaccine does not necessarily mean recognition of the intended tumor antigen. [4]
Laboratory measurements in these programs included phenotyping of immune cells, cytokine labeling, and antigen recognition tests.
They help determine whether the intervention stimulates the immune system.
However, they cannot independently prove that the immune cells reach the tumor and provide clinically relevant control of the tumor.
Mechanism of action studied in p53 peptide vaccines
The antigen presentation combines the vaccine material with the immune response.
The cell that presents the antigen processes or exposes peptide fragments in conjunction with HLA molecules, and the appropriate T lymphocytes can recognize the resulting complexes.
Scientists can then measure changes in the number of T lymphocytes, cytokine release, or antigen-specific responses.
However, each of these measurements only covers part of the multi-stage process.
For the immune response to affect the course of the tumor, the appropriate cells must also recognize the antigen presented in the patient's body and retain the ability to function in the tumor environment.
This is one of the reasons why monitoring of the immune response and evaluation of clinical results should be conducted together.
The vaccine can cause the formation of circulating antigen-reactive cells without demonstrating that these cells penetrate the tumor or remain functional there.
On the other hand, the clinical outcome in the study without a control group cannot be attributed solely to the vaccine, as the natural course of the disease and concomitant treatment may have an impact.
A convincing causal explanation requires several consistent types of evidence, not just one favorable biomarker.
The intended mechanism is a kind of immunological activation.
Peptides provide the material for antigen presentation, enabling T lymphocytes to recognize the peptide–HLA complex.
Depending on the vaccine design and the way the antigen is processed, the response may involve helper T cells, cytotoxic T cells, or both types of cells.
A broader or longer-lasting response may be biologically interesting, but it may not be effective against a particular patient's cancer.[1][3]
The studies also analyze the obstacles that hinder the functioning of the immune system.
Compared to the methods of administering the vaccine in patients with ovarian cancer, concomitant treatment with interleukin 2 was associated with serious toxic effects and an increase in the number of regulatory T lymphocytes.
This does not mean that one immunomodulatory component always produces the same effect.
It does, however, show that additional substances affecting the immune system can change both the safety and the interpretation of the vaccine experiment.[2]
Stabilized peptides mimicking p53 (stapled p53-mimetic peptides) belong to a different mechanistic category.
ALRN-6924 was studied as a peptide capable of penetrating cells and disrupting p53 inhibition by the MDM2 and MDMX proteins.
This approach is intended to affect p53 intracellular function rather than induce immunization against peptide antigens.
Its clinical results cannot be used to confirm the efficacy of p53 peptide vaccines. [8]
Limitations of scientific evidence regarding p53 peptide vaccines
Differences between the tumors themselves also influence the interpretation.
The expression of tumor antigens, previous treatment, immunosuppression, and the patient's condition may be different.
The anti-aging strategy studied after surgery may address a different clinical problem than the strategy evaluated in advanced disease.
Therefore, the results should be presented in their actual clinical context, rather than being generalized to all tumors containing a mutation in the TP53 gene.
Negative and ambiguous results are just as important as positive immunological measurements.
In further follow-up of the ovarian cancer program, no expected improvement in response to subsequent chemotherapy or disease-specific survival was observed compared to the historical control group.
This does not definitively rule out the effectiveness of any alternative formulation in another population.
However, this means that immunogenicity alone is not sufficient to establish a proven benefit in terms of survival.
A balanced scientific interpretation requires presenting both types of results.
The studies discussed confirm that some formulations can elicit measurable immunological responses.
However, they do not confirm the existence of a single clinically effective „p53 vaccine” that can be used in all cancers.
Differences regarding the type of tumor, the stage of the disease, HLA selection, prior treatment, peptide design, and concomitant therapy limit direct comparisons.
The most important questions concern whether the study had an appropriate control group, whether the endpoint was determined in advance, how many patients could be evaluated, and whether the clinical results improved.
The percentages of immune response should indicate a common denominator: patients included in the study, those treated, and those who completed all assessments do not always form the same group.
Small studies in early phases also provide limited information about rare adverse reactions and long-term outcomes.
The absence of serious events in several participants is a positive observation under these data conditions, but does not prove widespread safety.
The safety assessment concerns the entire formulation and the context of the treatment.
This review is intended as a focused narrative analysis, rather than a global audit of regulatory approvals or an exhaustive catalog of all immunotherapies directed against TP53.
The cited studies on peptide vaccines relate to experimental approaches.
Patents, research registrations and publications should not be presented as marketing authorisations, and the undefined „p53 vaccine” should not automatically take the place of evidence regarding another design.
How to interpret immunogenicity and clinical results?
The term „immunogenicity” means that the intervention caused a detectable immune response according to a specific test.
It does not in itself mean that the response was strong enough, properly targeted or sustained to change the course of the cancer disease.
For example, the detection of a measurable response in nine out of ten patients in a study of colon cancer is an important observation regarding the possibility of inducing an immune response.
However, this does not mean that a tumor response occurred in nine out of ten patients.
Similarly, the persistence of the immune response in six of the nine evaluated patients should not be presented as evidence of six sustained clinical remissions.[1]
Different immunological tests also have different significance.
Counting the lymphocytes that react to the antigen, measuring interferon gamma secretion, and demonstrating the recognition of actual tumor cells are not equivalent results.
The result may be technically correct, while at the same time answering a narrow biological question.
Reports should indicate the method of determination, the type of sample, the measurement time, and the denominator.
This helps distinguish the increase in immunological reactivity from evidence of effective tumor control.
Clinical endpoints require separate interpretation rules.
The stabilization of the disease is not equivalent to a complete or partial response.
Disease-free survival in a small single-arm study cannot confirm a causal advantage without appropriate comparison.
Historical control groups provide context, but may differ in the timing and duration of the use of specific treatment methods.
The most convincing studies will combine immunological evidence with previously established clinical results in a project that allows for a reliable assessment of causality.
Research priorities and unresolved questions
One of the priorities of future research is to determine which antigenic structures consistently elicit responses capable of recognizing the appropriate tumor targets.
This requires more than measuring the reactivity to the vaccine material provided.
Scientists must assess whether immune cells recognize the naturally processed antigen and whether the tumor biology enables such recognition.
The sequence design, HLA selection, and the use of auxiliary epitopes may be important, but each hypothesis requires verification.
The next priority is to separate the effect of the vaccine from the impact of the accompanying interventions.
Chemotherapy, cytokines, and dendritic cell preparations can alter the immune response and the tolerance to treatment.
Studies with appropriate comparison groups would make it easier to determine whether the addition of a specific peptide vaccine improves outcomes beyond the effects of the remaining elements of the treatment program.
Such projects would also help determine whether promising laboratory results correspond to clinically significant benefits.
Long-term observation is important for both effectiveness and safety.
Studies in early stages often involve small groups and focus on feasibility and immunological measurements.
Larger, carefully monitored studies are needed to characterize rare adverse reactions, the durability of immune responses, recurrence patterns, and outcomes that are important to patients.
These are unresolved research questions, not reasons to assume success or failure in advance.
Frequently asked questions about p53 peptide vaccines
1. Do peptide vaccines p53 mean one defined substance?
No. This term describes several experimental formulations. A mixture of long peptides, a selected short epitope, and dendritic cells prepared using peptides may appear under different names, despite significant differences. Therefore, before attributing study results to a product or comparing two studies, it is necessary to identify the exact structure and formulation. [2] In practical evidence tables, each formulation should have a separate column containing the number of peptides, the sequence type, an adjuvant or cell platform, and the population being studied. Otherwise, readers may randomly compare different interventions as if they were one standardized drug.
2. What do the available studies on p53 peptide vaccines confirm?
They confirm the immunological activity of some of the tested formulations, but provide much more limited evidence of clinical benefits. Further observation of one of the ovarian cancer programs did not show an improvement in survival compared to the historical control group. Therefore, the conclusion is justified by the immunogenicity of the specific formulations, rather than a proven general method of treating tumors or a benefit common to all approaches targeting p53. [7] Distinguishing between immunological activity and a clinical outcome is fundamental. The test may detect responding cells, while the study still lacks sufficient participants, control groups, or observation time to determine whether the vaccination changed the number of recurrences, symptoms, or survival.
3. Is the p53 peptide vaccine itself p53 protein?
No. The peptide vaccine uses a selected antigenic material, not necessarily the entire protein. The number and length of the sequences vary depending on the structure. This is important because immunological recognition depends on the presented material. Therefore, a study of a single selected fragment is not an experiment covering all possible p53 antigens. [5] The p53 protein contains many potential antigenic regions, but the specific vaccine provides the immune system with only a selected set. The selection of the sequence influences which epitopes can be processed and presented, therefore the results cannot be generalized to any possible fragment.
4. Do peptide vaccines p53 prevent cancer in healthy people?
The cited studies concerned therapeutic applications or situations following surgical treatment in people with a history of cancer. This is not equivalent to confirming prevention in healthy populations. The well-known word „vaccine” does not automatically specify the target group. Before interpreting the claim of preventing cancer, the actual inclusion criteria in the study must be verified. [3] The term „vaccine” can appear in both prophylactic and therapeutic studies. The populations and endpoints in the publications discussed concern the treatment of tumors or follow-up after treatment, therefore preventing the first diagnosis of a tumor would essentially require a different research program.
5. Does the TP53 mutation automatically mean that the patient is a suitable candidate for the vaccine?
No. The mutation status alone does not confirm the qualification or probability of a response. The protocol may also depend on the antigenic sequence, expression in the tumor, presentation by HLA, and the context of the disease. The cited ovarian cancer study used specific immunological criteria, which shows why a single genetic result cannot replace a full evaluation consistent with the protocol. [2] The clinical significance of TP53 mutation depends on more than just detecting the mutation in the report. The exact vaccine antigen, HLA type, expression, and presentation of the target must be considered, as well as the qualification criteria specified in the study.
6. Are wild-type p53 peptides and mutation-specific peptides interchangeable?
No. A mutation can alter the antigenic sequence and the appropriate immune response. The results regarding the wild-type peptide should remain attributed to that peptide until another construct is tested. The programs discussed using wild-type sequences cannot confirm efficacy against every mutated sequence specific to the patient simply because they are all related to the biology of TP53.[2] The antigen specific to the mutation may create a different recognition possibility than the wild-type antigen. This is an important scientific difference, but the existence of a potentially different epitope does not prove that a vaccine directed against it will provide clinical benefit.
7. Why is the HLA type important?
HLA molecules influence which peptide fragments can be presented for recognition by T lymphocytes. Therefore, some short peptide studies have selected participants with a specific HLA type. This limits the possibility of generalizing the results. A positive result in a HLA-matched group does not confirm the same presentation or immune response in individuals with a different HLA profile. [3] The limitation of HLA is important because the peptide must be presented in the appropriate molecular context. A study involving one HLA type can provide valuable information for this group, while remaining limited evidence for individuals who do not have the same presentation pathway.
8. What does the mixture of overlapping long peptides mean?
This means that neighboring synthetic sequences have common fragments of the same antigenic region. This solution provides many potential fragments for immunological processing, rather than relying on a single short sequence. However, broader coverage of the sequence does not in itself guarantee better tumor control. The actual formulation still requires experimental and clinical evaluation. [1] Overlaying peptides increases the range of regions available for processing, but they do not guarantee the same presentation of each fragment. The composition of the mixture, the processing by antigen-presenting cells, and the methods of monitoring immunity determine what the experiment can actually show.
9. Are dendritic cells loaded with peptides equivalent to free peptide formulations?
No. The cell platform changes the way antigen is prepared and presented. Comparisons must take into account the properties of the cells and other elements of the treatment, not just the identity of the peptide. Similar immunological results in a small study do not confirm the equivalence of platforms in terms of production, safety, or long-term clinical efficacy. [2] Dendritic cell preparations introduce variable production and biological properties beyond peptide chemistry. Cell viability, maturation degree, antigen loading, and the use of additional substances can complicate comparisons with a non-cellular vaccine.
10. Does the response in the ELISPOT test indicate the destruction of cancer cells?
No. ELISPOT can demonstrate a measurable response of immune cells in the test conditions, but does not demonstrate tumor destruction in the patient. Access of immune cells to the tumor, recognition of the target, and inhibition of the response in the tumor environment remain separate issues. The immunogenicity result is significant, but imaging, recurrence data, and survival data are also needed to assess clinical efficacy.[1] The ELISPOT test usually counts cells that produce a specific signal after stimulation. It does not directly demonstrate tumor destruction, does not confirm cell migration into the tumor tissue, nor determines the impact on survival. These results require separate measurements.
11. Does the stabilization of the disease prove the effectiveness of the vaccine?
No. Disease stabilization may have several explanations, especially in the absence of an appropriate control group. In the ovarian cancer study, limited disease stabilization was described without a clear link to the induced immune response. Assigning the effect of the intervention requires a design that distinguishes its effect from the natural course of the disease, prior treatment, and variability in measurements. Observation alone is not sufficient. [5] In early oncology studies, disease stabilization is a description of the state at a specific time point of the assessment. Without a control group, it is difficult to separate the contribution of natural disease variability, prior therapies, and selection of participants.
12. Does the study of combination therapy allow the independent contribution of the peptide to be determined?
Usually not, unless the study design explicitly separates the individual components. Chemotherapy, immunomodulators, and the vaccine can independently affect outcomes and toxicity. A small study of combination therapy provides information about feasibility and biological activity, but more reliable attribution of effect would require appropriate comparison groups or another design that allows isolation of the vaccine component. [6] A multi-component intervention may be promising without indicating which component contributed the most. Attribution of causality becomes more reliable when study groups allow for separate assessment of components or when additional evidence supports a specific explanation.
13. Are stabilized p53 peptides the same as p53 peptide vaccines?
No. Definition stapled The description describes a strategy for stabilizing the peptide structure, not a vaccine mechanism. ALRN-6924 was studied for interfering with the interactions of proteins that regulate p53, not as an antigenic vaccine. The classification should be based on the mechanism and formulation of the intervention, not on the mere presence of the words „p53” and „peptide” in its description. [8] Peptide structure stabilization is a chemical design strategy that can serve various purposes. Therefore, a peptide that penetrates cells and regulates p53 and a vaccine that delivers an antigen require different frameworks for evaluating the evidence, despite partially common terminology.
14. Does the patent prove that the p53 vaccine works?
No. A patent does not replace the controlled testing of clinical results. Patent claims may relate to sequences, production methods, formulations, or proposed uses. To assess the scientific evidence, one must first identify the exact design, then locate the experiments and evaluate their design. Patent ownership or a recognizable company name do not determine effectiveness. Patent documents can help identify proposed sequences and technical solutions, but the criteria for patentability differ from standards for demonstrating clinical efficacy. A patent should be treated as a document regarding the invention, not a report of treatment results.
15. Can the results of ovarian cancer tests be generalized to other tumors?
Not without relevant evidence in the new context. Tumor biology, treatment history, antigen presentation, and stage of disease may vary. The existence of separate programs for colorectal cancer and head and neck tumors shows why each clinical context requires evaluation, rather than assuming a uniform response to any p53-related antigen.[1][3] Even if tumors share a molecular commonality, their immunological environments and standard treatment methods may be different. Generalization should be based on studies in a new indication, not on a common molecular target name.
16. Does the recognition of vaccine components prove the recognition of p53?
No. These may be separate immunological measurements. In the study of idiotypic peptides, responses to administered peptides were observed without the T-cell responses characteristic of human p53. Scientists must therefore directly investigate the recognition of the intended antigen. The response to a formulation is not automatically evidence of recognition of the desired tumor target. [4] A test demonstrating an response to a given idiotypic peptide does not necessarily indicate recognition of the tumor-associated p53. Therefore, appropriately designed cross-recognition tests are needed, rather than assuming that any response specific to the antigen has an intended target.
17. What studies would provide stronger clinical evidence?
Stronger evidence would provide properly controlled studies demonstrating improvements in outcomes relevant to patients. They should precisely identify the vaccine, specify the eligible population, establish endpoints before the study begins, and monitor benefits and harms. Repeat immunological activity remains valuable supporting information, but should accompany evidence of improvement in tumor control, function, or survival, not replace it. Ideally, subsequent studies should include transparent characterization of the vaccine, appropriate randomization, blinded or objective evaluation of results, sufficiently long follow-up, and systematic safety monitoring. Immunological markers should help explain results, not replace their evaluation.
Applications
Evidence regarding p53 peptide vaccines should best be considered as additional research questions.
The first concerns whether the experimental vaccine was properly defined.
Second – whether it is able to elicit the intended immune response specific to the antigen.
Third – is this response detectable and biologically relevant in the tumor environment?.
The last and most important question is whether the intervention improves outcomes relevant to patients compared to the corresponding alternatives.
The cited studies answered part of the first two questions regarding the selected preparations, but did not provide a universally positive answer to the last question.
P53 peptide vaccines constitute a diverse research category.
Before drawing conclusions, it is necessary to identify their antigenic sequences, formulations, and accompanying interventions.
Some studies show immunological activation, while clinical efficacy remains much less well-established.
Separating the vaccines from the peptides that act on the intracellular p53 pathways and from the patent documents themselves prevents the aggregation of unrelated results into unfounded claims about the effectiveness of the treatment.
Educational, medical and regulatory reservations
The article is of an exclusively scientific and educational nature. It does not constitute medical advice, recommendations for the treatment of tumors, or instructions for the procurement, preparation, administration, or combination of experimental vaccines. The diagnosis and treatment of cancer require individual evaluation by qualified oncology specialists.
The described p53 peptide vaccines are experimental interventions, and their evidence relates to specific formulations. A detectable immune response does not prove tumor control, survival extension, or regulatory approval. Legal status depends on the product, indication, country, and date. Publication, patent, or registration in the research registry do not in themselves constitute a marketing authorization, and results regarding one formulation cannot be automatically transferred to others.
References
- Speetjens, F. M., Kuppen, P. J., Welters, M. J., Essahsah, F., Voet van den Brink, A. M., Lantrua, M. G., Valentijn, A. R., Oostendorp, J., Fathers, L. M., Nijman, H. W., Drijfhout, J. W., van de Velde, C. J., Melief, C. J., & van der Burg, S. H. (2009). Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clinical Cancer Research, 15(3), 1086–1095. https://doi.org/10.1158/1078-0432.CCR-08-2227
- Rahma, O. E., Ashtar, E., Czystowska, M., Szajnik, M. E., Wieckowski, E., Bernstein, S., Herrin, V. E., Shams, M. A., Steinberg, S. M., Merino, M., Gooding, W., Visus, C., Deleo, A. B., Wolf, J. K., Bell, J. G., Berzofsky, J. A., Whiteside, T. L., & Khleif, S. N. (2012). A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology, Immunotherapy, 61(3), 373–384. https://doi.org/10.1007/s00262-011-1100-9
- Schuler, P. J., Harasymczuk, M., Visus, C., Deleo, A., Trivedi, S., Lei, Y., Argiris, A., Gooding, W., Butterfield, L. H., Whiteside, T. L., & Ferris, R. L. (2014). Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clinical Cancer Research, 20(9), 2433–2444. https://doi.org/10.1158/1078-0432.CCR-13-2617
- Lomas, M., Liauw, W., Packham, D., Williams, K., Kelleher, A., Zaunders, J., & Ward, R. (2004). Phase I clinical trial of a human idiotypic p53 vaccine in patients with advanced malignancy. Annals of oncology : official journal of the European Society for Medical Oncology, 15(2), 324–329. https://doi.org/10.1093/annonc/mdh053
- Leffers, N., Lambeck, A. J., Gooden, M. J., Hoogeboom, B. N., Wolf, R., Hamming, I. E., Hepkema, B. G., Willemse, P. H., Molmans, B. H., Hollema, H., Drijfhout, J. W., Sluiter, W. J., Valentijn, A. R., Fathers, L. M., Oostendorp, J., van der Zee, A. G., Melief, C. J., van der Burg, S. H., Daemen, T., & Nijman, H. W. (2009). Immunization with a synthetic long peptide vaccine against P53 induces P53-specific immune responses in patients with ovarian cancer, a phase II study. International Journal of Cancer, 125(9), 2104–2113. https://doi.org/10.1002/ijc.24597
- Dijkgraaf, E. M., Santegoets, S. J., Reyners, A. K., Goedemans, R., Nijman, H. W., van Poelgeest, M. I., van Erkel, A. R., Smit, V. T., Daemen, T. A., van der Hoeven, J. J., Melief, C. J., Welters, M. J., Kroep, J. R., & van der Burg, S. H. (2015). A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget, 6(31), 32228–32243. https://doi.org/10.18632/oncotarget.4772
- Leffers, N., Vermeij, R., Hoogeboom, B. N., Schulze, U. R., Wolf, R., Hamming, I. E., van der Zee, A. G., Melief, K. J., van der Burg, S. H., Daemen, T., & Nijman, H. W. (2012). Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer. International Journal of Cancer, 130(1), 105–112. https://doi.org/10.1002/ijc.25980
- Saleh, M. N., Patel, M. R., Bauer, T. M., Goel, S., Falchook, G. S., Shapiro, G. I., Chung, K. Y., Infante, J. R., Conry, R. M., Rabinowits, G., Hong, D. S., Wang, J. S., Steidl, U., Naik, G., Guerlavais, V., Vukovic, V., Annis, D. A., Aivado, M., & Meric-Bernstam, F. (2021). Phase 1 trial of ALRN-6924, a dual inhibitor of MDMX and MDM2, in patients with solid tumors and lymphomas bearing wild-type TP53. Clinical Cancer Research, 27(19), 5236–5247. https://doi.org/10.1158/1078-0432.CCR-21-0715